Osamu Hataji
Overview
Explore the profile of Osamu Hataji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morikawa K, Takemura H, Kitayama K, Inaba S, Imaoka H, Hashitsume Y, et al.
Respir Investig
. 2025 Mar;
63(3):342-345.
PMID: 40086402
Background: Few studies have measured the resting energy expenditure (REE) in patients with interstitial lung disease (ILD). Whether REE characteristics in patients with chronic obstructive pulmonary disease (COPD) and ILD...
2.
Sakaguchi T, Iketani A, Ito K, Nishii Y, Katsuta K, Hataji O
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941767
Background: Recent advances in perioperative immunotherapies have led to a new era in the perioperative treatment of resectable, non-small cell lung cancer (NSCLC). Although the choice of neoadjuvant, adjuvant or...
3.
Tharavecharak S, Fujimoto H, Yasuma T, DAlessandro-Gabazza C, Toda M, Tomaru A, et al.
Cells
. 2024 Sep;
13(18.
PMID: 39329706
Idiopathic pulmonary fibrosis (IPF) is a progressive, often fatal lung disease characterized by tissue scarring and declining lung function. The promoter polymorphism rs35705950, a significant genetic predisposition for IPF, paradoxically...
4.
Ito A, Kano S, Tarukawa T, Suzuki Y, Sakaguchi T, Ito K, et al.
Front Oncol
. 2024 Sep;
14:1415729.
PMID: 39281386
Objectives: This study aimed to assess the intrinsic impacts of the expression of PD-L1 on postoperative recurrence and the prognosis in patients with ()-mutated lung adenocarcinomas. Patients And Methods: Data...
5.
Yasuma T, Fujimoto H, DAlessandro-Gabazza C, Gabazza E, Hataji O, Kobayashi T
Am J Respir Crit Care Med
. 2024 Sep;
210(10):1278.
PMID: 39270214
No abstract available.
6.
Imaoka Y, Hataji O
Respir Investig
. 2024 Aug;
62(6):976-979.
PMID: 39197379
Background: Presbyphagia, an age-related decline in swallowing function, is considered a precursor stage of dysphagia and a risk state that can lead to aspiration pneumonia and malnutrition. We examined factors...
7.
Sakaguchi T, Iketani A, Esumi S, Esumi M, Suzuki Y, Ito K, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730622
Some multi-gene panel tests have been implemented in clinical settings to guide targeted therapy in non-small-cell lung cancer (NSCLC) in Japan. The current performance of multi-gene panel tests under the...
8.
Morikawa K, Tabira K, Takemura H, Inaba S, Suzuki Y, Hataji O
Respir Investig
. 2024 Apr;
62(3):369-374.
PMID: 38637059
Background: There are no reports of exercise-induced hypoxemia in patients with coronavirus disease 2019 (COVID-19). Additionally, the predictive factors and prevalence of exercise-induced hypoxemia are unknown. This study investigated the...
9.
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, et al.
Cancer Med
. 2024 Apr;
13(8):e7188.
PMID: 38629295
Background: Immune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence...
10.
Ito K, Suzuki Y, Sakaguchi T, Fujiwara K, Nishii Y, Yasui H, et al.
JAMA Oncol
. 2024 Mar;
10(5):648-651.
PMID: 38546663
Importance: The Eastern Cooperative Oncology Group Performance Status (ECOG PS) is extensively used to guide treatment decisions in patients with advanced lung cancer. However, its assessment is subjective, potentially leading...